Rapamycin (sirolimus) is an FDA-approved immunosuppressant for preventing kidney transplant rejection, and its use for longevity is off-label.1,2 In mice, rapamycin started late in life raised the age at 90% mortality by 14% in females and 9% in males.3 In people, a 48-week placebo-controlled trial in healthy aging adults found similar side effects to placebo and no change in its primary outcome after 48 weeks.6 If you are considering it, a physician can set up the lab monitoring the label calls for.
What Rapamycin Is
Rapamycin is the common name for sirolimus, a prescription drug the label describes as an mTOR inhibitor immunosuppressant.1 Researchers describe it as an FDA-approved drug with immune-modulating and growth-inhibitory properties.2
Its standard use is in transplant medicine, where it keeps the immune system from attacking a new kidney.1 Its interest for longevity comes from animal studies in which blocking the same pathway extended lifespan.3,4 Both facts belong in any decision about it, and you should hear both from whoever prescribes it.
FDA Approval and Off-Label Longevity Use
The sirolimus tablet label lists two indications. It is approved to prevent organ rejection in people aged 13 or older receiving a kidney transplant, and to treat lymphangioleiomyomatosis (LAM), a rare lung disease.1
Longevity is not on the label. A 2023 survey study noted that several physicians are prescribing rapamycin off-label as a preventive therapy to maintain healthspan, the years lived in good health.2 The same authors stated that limited data exist on its side effects or efficacy in that setting.2
Off-label means the FDA has not reviewed rapamycin for healthy aging. If you take it for that purpose, your physician's job is to weigh the evidence, monitor your response and explain that reasoning to you.
The Mechanism Behind Rapamycin
Inside cells, sirolimus binds a protein called FKBP-12. The pair then blocks mTOR (mammalian target of rapamycin), an enzyme that controls cell growth.1 This blocks T-cell activation and multiplication, which is why the drug suppresses the immune response.1
The same pathway connects to aging research. A 2014 trial report states that mTOR inhibition extends lifespan in all species studied to date, while its effect on human aging is unknown.4 Lifespan extension in yeast, worms, flies and mice is the reason researchers are testing rapamycin in people. Those results do not predict what rapamycin will do for you.3,4
You can read more about how aging is measured in biological age, and how longevity care is structured in longevity medicine.
Lifespan Results in Mice
The landmark study fed rapamycin to genetically mixed mice starting at 600 days of age, which is late in a mouse's life.3 Rapamycin extended both median and maximum lifespan in males and females.3
Measured by the age at which 90% of the mice had died, the increase was 14% for females and 9% for males.3 The effect appeared at three separate test sites. The authors suggested rapamycin may work by postponing death from cancer, by slowing aging mechanisms, or both.3
These are mouse results. They justify human trials. When you see a human lifespan figure quoted from them, you are reading an extrapolation, and you can ask your physician what the human data show instead.
Human Trials of Rapamycin and Aging
Human data on rapamycin for aging come from a small number of trials, most measuring health markers over months. None measures lifespan, so each result is a signal you can weigh against your own goals.
The PEARL Trial
PEARL was a 48-week randomized, double-blind, placebo-controlled trial in healthy adults with normal aging.6 Participants took placebo or compounded rapamycin at one of two weekly dose levels.6
The primary outcome was visceral fat, the fat around the organs, measured by DXA scan. It did not change.6 Blood biomarker changes stayed within normal ranges, and adverse events were similar across all groups.6
Four secondary measures improved in specific dose groups. Women in the higher-dose group showed improvements in lean tissue mass and self-reported pain that reached statistical significance.6 The lower-dose group reported better emotional well-being and general health.6 No other effects were found. The authors concluded that this schedule was relatively safe over 48 weeks and that efficacy still needs to be established.6
Immune and Physiological Measures
A 2014 trial in older volunteers tested RAD001, another mTOR inhibitor. It enhanced the response to the influenza vaccine by about 20%.4 That points to better immune function in older adults, an aging-related measure. It is not a lifespan result.
A 2024 systematic review pooled 19 human studies of rapamycin and its derivatives.5 They improved aging-related measures in the immune, cardiovascular and skin systems. No effect was found on the endocrine, muscular or neurological systems.5
Practical takeaway: the human trials found short-term changes in specific markers, and none measured lifespan. If you start rapamycin, a defined marker that your physician tracks over time gives you a fair test.
Side Effects and Label Warnings
The sirolimus label carries a boxed warning. Immunosuppression can increase susceptibility to infection and the possible development of lymphoma and other malignancies.1 That warning comes from transplant patients on daily treatment, a different setting from intermittent longevity use, but it explains why monitoring matters.
The label lists other warnings that apply to anyone considering it:1
- Cholesterol and triglycerides: these rose more often with sirolimus than with control treatments, and the label calls for lipid monitoring in anyone taking it.
- Wound healing: impaired or delayed healing has been reported.
- Male fertility: azoospermia or oligospermia, an absent or low sperm count, may occur.
- Vaccines: live vaccines should be avoided.
The 2024 review found no serious adverse events attributed to rapamycin in healthy people. People with aging-related diseases had more infections and higher total cholesterol, LDL cholesterol and triglycerides.5
If you plan to have children, have surgery coming up, or are due a live vaccine, raise it before you start. Each one changes the timing or the decision.
Physician Monitoring on Rapamycin
Monitoring starts before the first prescription. Your physician needs a baseline lipid panel, because the label calls for monitoring cholesterol and triglycerides.1 Your infection history and vaccination plans come next, given the immunosuppression warning.1
From there, repeat labs show whether your lipids, blood counts and other markers are holding steady. PEARL found blood biomarker changes within normal ranges in healthy adults.6 Your own repeat panel tells your physician whether that holds for you.
Rapamycin is one option among several in longevity care. Metformin is another drug studied for aging, and longevity supplement stacks covers what public figures say they take. Your physician can compare these against your labs and goals.
The Opt Take on Rapamycin for Longevity
Rapamycin is a drug that needs follow-up labs, so the plan around it matters as much as the prescription. At Opt Health, your starting point is a blood panel of 55+ biomarkers spanning hormones, inflammation, cardiovascular risk and more. Your existing conditions and current medications are reviewed at your initial consultation.
A physician reads your results with you 1:1 and builds a plan that can include prescriptions, peptides and supplements. The Longevity tier adds 65+ biomarkers, epigenetic testing for biological age and a 90-minute consultation.
Labs and a physician consultation repeat every 3 to 4 months. For a drug with a lipid warning, that cadence lets your physician see your cholesterol and triglycerides change and adjust your plan on what your numbers did.
Get started: Begin with Opt Health, where a physician reads your labs, builds your plan, and adjusts it over the loop.
Frequently Asked Questions
Rapamycin for longevity is the off-label use of sirolimus, a transplant drug, with the aim of slowing aging.1,2 It blocks mTOR, a growth pathway linked to lifespan in animal studies.3,4 Human trials have measured health markers over months, so a physician treats it as an experiment with defined markers to track.5,6
Yes, for specific conditions. Sirolimus is FDA-approved to prevent organ rejection in kidney transplant recipients aged 13 or older and to treat LAM.1 It is not approved for longevity or healthy aging, so that use is off-label and calls for physician monitoring.2
Rapamycin binds a protein called FKBP-12, and the pair blocks mTOR, an enzyme that controls cell growth.1 That suppresses T-cell activation, which is how it prevents transplant rejection.1 The same pathway is linked to lifespan in animal studies.4 Your physician weighs both effects when deciding whether it fits you.
No human study has measured how much rapamycin extends life. In mice started late in life, it raised the age at 90% mortality by 14% in females and 9% in males.3 The PEARL trial in healthy adults ran 48 weeks and measured health markers over that period.6 Treat any human lifespan figure as an extrapolation from mice.
Rapamycin increases lifespan in mice.3 Whether it does in people is unknown, as the authors of a 2014 human trial stated directly.4 Human studies have found changes in some aging-related markers, including immune and cardiovascular measures.5 If you try it, your physician can track the markers that matter for your plan.
Rapamycin calls for baseline and repeat labs, including lipids. An Opt Health membership pairs 55+ biomarkers with a 1:1 physician review, then repeats labs and a physician consultation every 3 to 4 months.
References
- Glenmark Pharmaceuticals Inc., USA. Sirolimus tablets, for oral use. Prescribing information. DailyMed. Published January 29, 2026. Accessed October 14, 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=57fb4d90-3ccb-4a69-af1e-53be83f7a504
- Kaeberlein TL et al. Evaluation of off-label rapamycin use to promote healthspan in 333 adults. Geroscience. 2023;45(5):2757-2768. https://pubmed.ncbi.nlm.nih.gov/37191826/
- Harrison DE et al. Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. Nature. 2009;460(7253):392-395. https://pubmed.ncbi.nlm.nih.gov/19587680/
- Mannick JB et al. mTOR inhibition improves immune function in the elderly. Sci Transl Med. 2014;6(268):268ra179. https://pubmed.ncbi.nlm.nih.gov/25540326/
- Lee DJW et al. Targeting ageing with rapamycin and its derivatives in humans: a systematic review. Lancet Healthy Longev. 2024;5(2):e152-e162. https://pubmed.ncbi.nlm.nih.gov/38310895/
- Moel M et al. Influence of rapamycin on safety and healthspan metrics after one year: PEARL trial results. Aging (Albany NY). 2025;17(4):908-936. https://pubmed.ncbi.nlm.nih.gov/40188830/
This content is for informational purposes and does not replace evaluation, diagnosis, or treatment by a qualified medical professional.
This article is part of our guide to longevity. See how longevity medicine works at Opt Health.
Start Today
Your health, your terms. Discover how personalized care can transform not just the way you feel, but how you live.